Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biossci is a Wuhan-based life science research services company that operates as a CRO focused on pathology and related preclinical laboratory services. The company provides integrated experimental support spanning pathology, molecular biology, protein immunology, cell biology, bioanalysis, and animal-model pathology evaluation, and also sells research reagents, consumables, and instruments. Public descriptions emphasize its role as a service provider for medical researchers and pharmaceutical R&D companies rather than as a developer of a disclosed therapeutic pipeline. Biossci appears to have built a multi-city service network in China and promotes a central laboratory of about 4,000 square meters with broad technical capabilities. The company has also announced expansion into clinical development-related collaboration around depression diagnostics and nanobody drug technologies, but no named internal drug candidates are publicly detailed.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biossci.